Aurora Cannabis rejects Curaleaf bid, defends at-the-market share program
ACB•Aurora rejects Curaleaf bid as inadequate
Aurora Cannabis rejected Curaleaf’s bid as inadequate, urging shareholders to take no action and not tender shares.
Company defends at-the-market program and raises regulatory complaint
The response challenged Curaleaf’s move to halt Aurora’s at-the-market program, calling it a distraction from valuation.
Aurora said the ATM was disclosed in February 2026, predates the bid, has been inactive for weeks, and was unused for three years.
The company highlighted Curaleaf’s balance sheet, citing more than $1 billion of debt, including $500 million at 11.5%.
Aurora said it raised a complaint with the Alberta Securities Commission on Sept. 2 over alleged regulatory deficiencies in the bid.
